On Monday, Relay Therapeutics Inc (NASDAQ: RLAY) opened lower -3.54% from the last session, before settling in for the closing price of $6.5. Price fluctuations for RLAY have ranged from $1.77 to $7.07 over the past 52 weeks.
During the last 5-year period, the sales drop of Healthcare Sector giant was -23.05%. Company’s average yearly earnings per share was noted 22.28% at the time writing. With a float of $130.15 million, this company’s outstanding shares have now reached $171.69 million.
Let’s determine the extent of company efficiency that accounts for 261 employees.
Relay Therapeutics Inc (RLAY) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Relay Therapeutics Inc is 24.51%, while institutional ownership is 78.62%. The most recent insider transaction that took place on Jul 29 ’25, was worth 57,864. In this transaction an insider of this company sold 15,724 shares at a rate of $3.68, taking the stock ownership to the 377,998 shares. Before that another transaction happened on Jul 28 ’25, when Company’s insider sold 1,359 for $3.74, making the entire transaction worth $5,083. This insider now owns 393,722 shares in total.
Relay Therapeutics Inc (RLAY) Recent Fiscal highlights
If we go through the results of last quarter, which was made public on 9/30/2024, the company posted -0.63 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -0.78) by 0.15. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.38 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 22.28% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 7.46% during the next five years compared to -23.05% drop over the previous five years of trading.
Relay Therapeutics Inc (NASDAQ: RLAY) Trading Performance Indicators
Check out the current performance indicators for Relay Therapeutics Inc (RLAY). In the past quarter, the stock posted a quick ratio of 20.92. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 129.31.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.95, a number that is poised to hit -0.42 in the next quarter and is forecasted to reach -1.75 in one year’s time.
